• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to secondary sidebar

OINDPnews


Proveris Scientific
  • Home
  • News
    • Business
    • Features
    • Medical
    • Regulatory
    • Products and Services
    • People
  • Events
  • Suppliers
    • Supplier listing and advertising options
    • Capsules and blisters
    • Consultants
    • Contract research
    • Contract manufacturing
    • Devices
    • Education
    • Excipients
      • Clinical Technology
    • Filling equipment
    • Instruments
    • Particle manufacturing
    • Software and modeling
  • Jobs
  • Resources
    • Webinars
    • White papers
  • LGWP Propellants
    • HFA 152a
    • HFO-1234ze(E)
    • LGWP Regulation
  • Contact

Medical

Cyrano announces Phase 1 trial of CYR-064 intranasal theophylline in Parkinson’s disease patients

Cyrano Therapeutics announced the launch of a Phase 1 study of CYR-064 intranasal theophylline in Parkinson's disease patients that is being conducted by David Silvers of Gardens Neurology in Palm Beach, Florida. Cyrano is developing the theophylline nasal spray for the restoration of the sense of smell in patients with reduced or absent sense of smell. In 2023, … [Read more...] about Cyrano announces Phase 1 trial of CYR-064 intranasal theophylline in Parkinson’s disease patients

GH Research says Phase 2b trial of GH001 inhaled mebufotenin met primary endpoint

GH Research announced that a Phase 2b clinical trial of GH001 inhaled synthetic mebufotenin (5-MeO-DMT) in patients with treatment-resistant depression met its primary endpoint, demonstrating a significant reduction in depression symptoms as measured by the Montgomery-Åsberg Depression Rating Scale (MADRS) on Day 8 post dose. All secondary endpoints were also met, the … [Read more...] about GH Research says Phase 2b trial of GH001 inhaled mebufotenin met primary endpoint

Inhalon announces plans for Phase 2a challenge study of IN-002 inhaled antibody against RSV

Inhalon Biopharma announced that it has contracted with hVIVO to conduct a Phase 2a challenge study of nebulized IN-002, an antibody against RSV, now that Inhalon has completed IND-enabling studies. The company said that it expects to initiate the trial of IN-002 in 2026. Inhalon's pipeline of inhaled antibodies also includes IN-003 against metapneumovirus, IN-005 … [Read more...] about Inhalon announces plans for Phase 2a challenge study of IN-002 inhaled antibody against RSV

FDA clears Kinaset’s IND for a Phase 2b trial of KN-002 frevecitinib DPI in patients with asthma

According to Kinaset Therapeutics, the FDA has cleared the company's IND for a Phase 2b trial of its KN-002 frevecitinib dry powder inhaler. The 12-week Phase 2 trial, which will evaluate 3 doses of dry powder frevecitinib in patients with severe asthma that is not adequately controlled by ICS / LABA therapy, is expected to get underway in mid-2025. Kinaset acquired … [Read more...] about FDA clears Kinaset’s IND for a Phase 2b trial of KN-002 frevecitinib DPI in patients with asthma

Ethris announces results of Phase 1 trial of ETH47 intranasal mRNA therapy, plans for Phase 2a trial

German biotech company Ethris announced that a Phase 1 trial of intranasal ETH47 mRNA therapy in healthy volunteers demonstrated "a clear dose-dependent production of IFNλ [interferon lambda] in the nasal lining fluid exceeding predicted therapeutic levels" without any serious or severe adverse events. The company had announced in December 2023 that it was initiating … [Read more...] about Ethris announces results of Phase 1 trial of ETH47 intranasal mRNA therapy, plans for Phase 2a trial

InvisiShield says it is accelerating development of its intranasal antibodies against all influenza A&B, including H5N1 bird flu

InvisiShield Technologies said that it will speed up its H5N1 / Pan-influenza intranasal antibodies development program in response to recent outbreaks of H5N1 avian flu in mammals. The company says that it can move quickly into clinical development because it previously held successful pre-IND meetings with the FDA regarding its IS101 intranasal antibody fusion … [Read more...] about InvisiShield says it is accelerating development of its intranasal antibodies against all influenza A&B, including H5N1 bird flu

Beckley announces results of Phase 2a trial of BPL-003 intranasal synthetic 5-MeO-DMT in alcohol use disorder

Beckley Psytech announced that a Phase 2a study of BPL-003 intranasal synthetic 5-MeO-DMT in people with alcohol use disorder demonstrated "meaningful and sustained reductions in alcohol use" for as long as 3 months post dose, with no serious or severe adverse events. The study, which was primarily designed to evaluate safety, enrolled 12 subjects with … [Read more...] about Beckley announces results of Phase 2a trial of BPL-003 intranasal synthetic 5-MeO-DMT in alcohol use disorder

FDA clears IND for a Phase 1 trial of Ocugen’s OCU500 COVID-19 vaccine via inhalation and nasal administration

Ocugen, Inc. announced that the FDA has cleared an IND for a Phase 1 trial of OCU500 vaccine for the prevention of COVID-19, which the company licensed from Washington University in St. Louis in 2022. The trial, which will evaluate inhaled and intranasal administration of the vaccine, will be conducted by the NIH's National Institute of Allergy and Infectious … [Read more...] about FDA clears IND for a Phase 1 trial of Ocugen’s OCU500 COVID-19 vaccine via inhalation and nasal administration

Belhaven Biopharma raises $11 million for development of Nasdepi intranasal dry powder epinephrine, initiates clinical trial

North Carolina-based Belhaven Biopharma announced that it has closed a funding round that raised $11 million for continued development of the company's Nasdepi intranasal dry powder epinephrine for the treatment of anaphylaxis. The company said that the funds will support the completion of clinical development and preparations for an NDA submission. Belhaven also … [Read more...] about Belhaven Biopharma raises $11 million for development of Nasdepi intranasal dry powder epinephrine, initiates clinical trial

Vistagen initiates Phase 2 repeat dose study of fasendiol nasal spray

Vistagen has announced the initiation of a Phase 2 repeat dose study of fasedienol nasal spray, which the company is developing for the treatment of social anxiety disorder. The Phase 3 PALISADE-3 and PALISADE-4 trials of fasendiol for that indication are ongoing. According to Vistagen, the design of the Phase 2 repeat dose trial is basically the same as the … [Read more...] about Vistagen initiates Phase 2 repeat dose study of fasendiol nasal spray

  • « Previous Page
  • Page 1
  • Page 2
  • Page 3
  • Page 4
  • Page 5
  • Interim pages omitted …
  • Page 119
  • Next Page »

Primary Sidebar

Sign up for our free weekly newsletter

Upcoming Events
Sponsored by Intertek

Want information about upcoming OINDP-related events delivered directly to your inbox? click here

  • June 17-June 18: Rescon Europe 2025, Paris, France
  • June 19-June 20: Metered Dose Inhaler (MDI) Technology Training Course, online
  • June 22-June 25: ISAM Congress 2025, Washington, DC, USA
  • June 25-June 25: SMI.London 2025, London, UK
  • September 18-September 19: IPAC-RS Nasal Innovation Forum, West Trenton, NJ, USA
  • See all upcoming events

    Secondary Sidebar

    Suppliers

    Capsules and blisters
    Consultants
    Contract research
    Contract manufacturing
    Devices
    Education
    Excipients
    Filling equipment
    Instruments
    Particle manufacturing
    Software and modeling
    Intertek banner
    Bespak Leading the Green Transition banner
    © 2025 OINDPnews